Modern Chemistry & Applications

Microcrylaq: A new way to implement quantum computation algebraic calculations in a 3D logical space for the discovery of a novel chemical antagonist against the two crizotinib resistant ALK mutations, G1202R and F1174C

Joint Event on 19^th International Conference on Medicinal Chemistry & Multi Targeted Drug Delivery & International Conference on Catalysis and Pyrolysis

November 05-06, 2018 | San Francisco, USA

Ioannis Grigoriadis

Biogenea Pharmaceuticals Ltd., Greece

Keynote: Mod Chem Appl

Abstract:

The Lindenbaum-Tarski algebra has been previously introduced as a 3D logical space in which anyone (of the eigenvalue statements) occupies a well-defined position and it is identified by a numerical ID. This allows pure mechanical computation both for generating rules and inferences. It is shown that this abstract formalism can be geometrically represented with logical spaces and subspaces allowing a vectorial representation. Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib. It has been previously been reported the first preclinical evaluation of the next-generation ALK TKI, ceritinib (LDK378) in the setting of crizotinib resistance. Interrogation of in vitro and in vivo models of acquired resistance to crizotinib, including cell lines established from biopsies of crizotinib-resistant NSCLC patients revealed that ceritinib potently overcomes crizotinib resistance mutations. In particular, ceritinib effectively inhibits ALK harboring L1196M, G1269A, I1171T and S1206Y mutations and a co-crystal of ceritinib bound to ALK provides structural bases for this increased potency. However, it has been observed that ceritinib did not overcome two crizotinib-resistant ALK mutations, G1202R and F1174C. Finally, we show the application to quantum computing through the example of three coupled harmonic oscillators as orthogonal applied for the design of a novel multi-chemo-structure against the two crizotinib-resistant ALK mutations, G1202R and F1174C mutations in a MicrocrylaqTM Lindenbaum-Tarski generated QSAR automating modeling lead compound design approach.

Biography :

Ioannis Grigoriadis has completed his PharmacistD at the age of 24 years from Aristotle University of Thessaloniki. He is the scientific director of Biogenea Pharmaceuticals Ltd., a premier biotechnology personalized cancer vaccination service organization. He has published more than 200 papers in reputed drug designing journals.

E-mail: jgrigoriadis@biogenea.gr